Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review outlines various non-rash skin toxicities associated with novel targeted anticancer therapies and provides guidelines for their early diagnosis and management, but reports no new clinical results.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

This review highlights that dermatologic side effects of cancer therapies, such as chemotherapy and immunotherapy, are increasingly complex, emphasizing the importance of preventive and management strategies to reduce skin toxicity and improve treatment adherence.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This study reported that chemotherapy-induced skin reactions in cancer patients are mostly mild to moderate and manageable with supportive care, suggesting that early dermatologic intervention can improve patient outcomes without interrupting chemotherapy.

Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

In this study, 96% of children with CNS tumors receiving MAPK and mTOR inhibitors experienced common, treatable skin reactions, occasionally requiring therapy adjustments.

This article reviews common skin eruptions in chemotherapy patients and discusses how recognizing these patterns can help avoid unnecessary changes to cancer treatment; it reports no new clinical results.

This review discusses various skin side effects from chemotherapy, noting that they are mainly toxic rather than allergic and often include alopecia, which can cause significant distress to patients.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This study reported that while both sorafenib and lenvatinib may require dose modifications due to adverse events in treating advanced or metastatic thyroid cancers, key differences in side effect profiles were observed.

In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.

This review discusses the adverse skin effects of EGFR inhibitors used in cancer treatment, exploring their mechanisms and offering strategies for prevention and management, but reports no new experimental findings.

This study found that adjuvant sorafenib after hepatic resection improved overall survival in patients with intermediate and advanced hepatocellular carcinoma, compared to surgery only.

This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.

This study reports that targeted anticancer therapies frequently cause skin-related side effects, which may impact patient adherence and quality of life, but these effects are positively correlated with treatment response.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.

This meta-analysis found that combined BRAF and MEK inhibitor treatment in melanoma patients is linked to increased all-grade rash but reduced risks of several other dermatological toxicities compared to BRAF inhibition alone.

This review discusses the various skin, mucosa, and adnexa side effects associated with different chemotherapeutic agents and provides insights into their clinical presentation and management; it reports no new results.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This review reports that treatments for urological cancers, such as chemotherapy and immunotherapy, often result in significant dermatological side effects that negatively affect patients' quality of life and treatment adherence, highlighting a need for better management strategies and further research.

This review discusses common cutaneous reactions to targeted cancer drugs such as tyrosine kinase inhibitors and reports no new clinical results.

Plaquenil can cause a severe skin reaction called AGEP, requiring prompt diagnosis and treatment.

This study highlights the significant impact of cutaneous side effects associated with anticancer therapies, emphasizing the need for proactive management to improve patient quality of life and treatment adherence.

The document concludes that various treatments for skin conditions are effective, but some require further research, and certain factors like gender and lifestyle can influence disease outcomes.

In this case report, a patient on low-dose sorafenib for hepatocellular carcinoma developed a rare and severe facial acneiform eruption without other skin side effects, which improved only minimally with topical treatment.